

Additional Table 1. Summary of the studies included in the pooled analyses

Study	Study design	Lost-to-follow-up	IPTp	ITN	Gestational age estimation	Outcomes included in the analysis				
						Congenital abnormality	Miscarriage /stillbirth	Small-for-gestational age	Preterm	Placental histopathology
Shared studies										
McGready, 2000[1]	RCT	13/111	Not applicable (Asia)	>90% in this study area*	Fundal height + Dubowitz	Yes	Yes	Yes	Yes	Not assessed
McGready, 2001a[2]	RCT	11/130	Not applicable (Asia)	>90% in this study area*	Fundal height + Dubowitz	Yes	Yes	Yes	Yes	Not assessed
McGready, 2005[3]	RCT	7/81	Not applicable (Asia)	>90% in this study area*	Ultrasound	Yes	Yes	Yes	Yes	Yes
Kalilani, 2007[4]	RCT	9/46	The second dose of the same drug was administered at least 4 weeks after the first dose instead of IPTp	Given to all at enrolment.	Ballard score	Yes	Yes	Yes	Yes	Not assessed
McGready, 2008[5]	RCT	8/246	Not applicable (Asia)	>90% in this study area*	Ultrasound	Yes	Yes	Yes	Yes	Not assessed
Piola, 2010[6]	RCT	53/292	Interrupted until delivery	Given to all at enrolment.	Ultrasound	Yes	Yes	Yes	Yes	Yes
D'Alessandro, 2016[7, 8]	RCT	134/3384	Interrupted for 63 days of follow-up	Given to all at enrolment.	Ultrasound (EGA in week)	Yes	Yes	Yes	Yes	Yes
Anvikar, 2018[9]	RCT	6/244	Not applicable (Asia)	Information not available	Ultrasound	Yes	Yes	Yes	Yes	Not assessed
McGready, 2003a[10]	PK study	3/27	Not applicable (Asia)	>90% in this study area*	Fundal height + Dubowitz	Yes	Yes	Yes	Yes	Not assessed
McGready, 2012[11]	PK study	3/19	Not applicable (Asia)	>90% in this study area*	Ultrasound	Yes	Yes	Yes	Yes	Not assessed
Rijken, 2011[12]	PK study	3/25	Not applicable (Asia)	>90% in this study area*	Ultrasound	Yes	Yes	Yes	Yes	Not assessed

Additional Table 1 continued.

Study	Study design	Lost-to-follow-up	IPTp	ITN	Gestational age estimation	Outcomes included in the analysis				
						Congenital abnormality	Miscarriage /stillbirth	Small-for-gestational age	Preterm	Placental histopathology
Valea, 2014[13]	PK study	1/21	IPTp-SP x 2	Offered to all at enrolment.	LMP or fundal height	Yes	Yes	Yes	Yes	Not assessed
Ndiaye, 2011[14]	Single-arm	0/26	Information not available	Information not available	Fundal height + Dubowitz (No EGA at delivery)	Yes	No (EGA at delivery is not available)	No (EGA at delivery is not available)	No (EGA at delivery is not available)	Not assessed
McGready, 2003b[15]	Observational cohort	0/24	Not applicable (Asia)	>90% in this study area*	Fundal height + Dubowitz	Yes	Yes	Yes	Yes	Not assessed
Rijken, 2008[16]	Observational cohort	5/48	Not applicable (Asia)	>90% in this study area*	Ultrasound	Yes	Yes	Yes	Yes	Not assessed
Kalilani, 2013[17, 18]	Observational cohort	6/41	IPTp-SP x 3	Given to all at enrolment.	LMP + fundal height + Ballard score	Yes	Yes	Yes	Yes	Yes
Studies not included										
Adam, 2004a[19]	RCT	0/42	Information not available	Information not available	Not specified	Not reported	Assessed	Not assessed	Assessed	Not assessed
Adam, 2004c[20]	Single-arm	0/28	Information not available	Information not available	Ultrasound	Assessed	Assessed	Not assessed	Assessed	Not assessed
Adam, 2006[21]	Single-arm	0/32	Information not available	Information not available	Ultrasound	Assessed	Assessed	Not assessed	Assessed	Not assessed
Adam, 2012[22]	PK study	0/12	Information not available	Information not available	Ultrasound	Assessed	Assessed	Not assessed	Assessed	Not assessed
Bounyasong, 2001[23]	RCT	3/57	Not applicable (Asia)	Information not available	Ultrasound	Assessed	Not clear	IUGR	EGA at delivery	Calcification of placenta
Mutabingwa, 2009[24]	RCT	5/83	Information not available	Information not available	Dubowitz	Assessed	Assessed	Not assessed	Assessed	Not assessed

EGA: estimated gestational age, IPTp: intermittent preventive treatment in pregnancy, ITN: insecticide-treated bed nets, IUGR: intrauterine growth restriction, LMP: last menstrual period, PK: pharmacokinetic, RCT: randomized control trial, SP: sulfadoxine-pyrimethamine

* reported by Boel *et al.* [25]

Reference for additional files

1. McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C, Chongsuphajaisiddhi T, White NJ, Nosten F: Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2000, 94(6):689-693.
2. McGready R, Cho T, Samuel, Villegas L, Brockman A, van Vugt M, Looareesuwan S, White NJ, Nosten F: Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2001, 95(6):651-656.
3. McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, Looareesuwan S, White NJ, Nosten F: A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. *J Infect Dis* 2005, 192(5):846-853.
4. Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Alker AP, Kwiek JJ, Meshnick SR: A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. *PLoS One* 2007, 2(11):e1166.
5. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, Wüstefeld K, Barends M, Laochan N, Keereecharoen L *et al*: A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. *PLoS Med* 2008, 5(12):e253.
6. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, Snounou G, Ashley Ea, McGready R, Nosten F *et al*: Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. *Lancet Infect Dis* 2010, 10(11):762-769.
7. PREGACT Study Group, Pekyi D, Ampromfi AA, Tinto H, Traoré-Coulibaly M, Tahita MC, Valéa I, Mwapasa V, Kalilani-Phiri L, Kalanda G *et al*: Four artemisinin-based treatments in African pregnant women with malaria. *N Engl J Med* 2016, 374(10):913-927.
8. Nambozi M, Kabuya J-BB, Hachizovu S, Mwakazanga D, Mulenga J, Kasongo W, Buyze J, Mulenga M, Van Geertruyden J-P, D'Alessandro U: Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria. *Malar J* 2017, 16:199.
9. Anvikar AR, Kuepfer I, Mishra V, Bruce J, Arya T, Mishra DR, Mohanty S, Mohanty R, Srivastava B, Sharma S *et al*: Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial. *Malar J* 2018, 17:246.
10. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F: The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. *Eur J Clin Pharmacol* 2003, 59(7):545-552.
11. McGready R, Phyto AP, Rijken MJ, Tarning J, Lindegardh N, Hanpithakpon W, Than HH, Hlaing N, Zin NT, Singhasivanon P *et al*: Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. *Br J Clin Pharmacol* 2012, 73(3):467-477.
12. Rijken MJ, McGready R, Phyto AP, Lindegardh N, Tarning J, Laochan N, Than HH, Mu O, Win AK, Singhasivanon P *et al*: Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. *Antimicrob Agents Chemother* 2011, 55(12):5500-5506.
13. Valea I, Tinto H, Traore-Coulibaly M, Toe LC, Lindegardh N, Tarning J, Van Geertruyden J-P, D'Alessandro U, Davies GR, Ward SA: Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. *J Antimicrob Chemother* 2014, 69(9):2499-2507.
14. Ndiaye JL, Ndiaye A, Faye B, Ba M, Tine R, Ndiaye D, Gaye A, Gaye O, Brasseur P: Open-label in vivo drug study to evaluate the safety and efficacy of artesunate plus amodiaquine

- combination in pregnant women with uncomplicated *P. falciparum* malaria in Senegal. *Trop Med Int Health* 2011, 16(Supplement 1):140.
15. McGready R, Keo NK, Villegas L, White NJ, Looareesuwan S, Nosten F: Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant *Plasmodium falciparum* malaria in pregnancy: a preliminary report. *Trans R Soc Trop Med Hyg* 2003, 97(5):592-594.
 16. Rijken MJ, McGready R, Boel ME, Barends M, Proux S, Pimanpanarak M, Singhasivanon P, Nosten F: Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant *Plasmodium falciparum* malaria in pregnancy: a preliminary report. *Am J Trop Med Hyg* 2008, 78(4):543-545.
 17. Cohee LM, Kalilani-Phiri L, Mawindo P, Joshi S, Adams M, Kenefic L, Jacob CG, Taylor TE, Laufer MK: Parasite dynamics in the peripheral blood and the placenta during pregnancy-associated malaria infection. *Malar J* 2016, 15:483.
 18. Kalilani-Phiri L, Thesing PC, Nyirenda OM, Mawindo P, Madanitsa M, Membe G, Wylie B, Masonbrink A, Makwakwa K, Kamiza S *et al*: Timing of malaria infection during pregnancy has characteristic maternal, infant and placental outcomes. *PLoS One* 2013, 8(9):e74643.
 19. Adam I, Ibrahim MH, A/elbasit IA, Elbashir MI: Low-dose quinine for treatment of chloroquine-resistant *falciparum* malaria in Sudanese pregnant women. *East Mediterr Health J* 2004, 10(4/5):554-559.
 20. Adam I, Elwasila E, Mohammed Ali DA, Elansari E, Elbashir MI: Artemether in the treatment of *falciparum* malaria during pregnancy in eastern Sudan. *Trans R Soc Trop Med Hyg* 2004, 98(9):509-513.
 21. Adam I, Ali DM, Abdalla MA: Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated *Plasmodium falciparum* malaria during pregnancy in eastern Sudan. *Trans R Soc Trop Med Hyg* 2006, 100(7):632-635.
 22. Adam I, Tarning J, Lindegardh N, Mahgoub H, McGready R, Nosten F: Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated *Plasmodium falciparum* malaria. *Am J Trop Med Hyg* 2012, 87(1):35-40.
 23. Bounyasong S: Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat *P. falciparum* malaria pregnant women. *J Med Assoc Thai* 2001, 84(9):1289-1299.
 24. Mutabingwa TK, Muze K, Ord R, Briceño M, Greenwood BM, Drakeley C, Whitty CJM: Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanil-dapsone and SP for malaria in pregnancy in Tanzania. *PLoS One* 2009, 4(4):e5138.
 25. Boel ME, Rijken MJ, Leenstra T, Phyto AP, Pimanpanarak M, Keereecharoen NL, Proux S, Laochan N, Imwong M, Singhasivanon P *et al*: Malaria in the post-partum period; a prospective cohort study. *PLoS One* 2013, 8(3):e57890.
 26. Adam I, Idris HM, Elbashir MI: Quinine for chloroquine-resistant *falciparum* malaria in pregnant Sudanese women in the first trimester. *East Mediterr Health J* 2004, 10(4/5):560-565.
 27. Onyamboko MA, Meshnick SR, Fleckenstein L, Koch MA, Atibu J, Lokomba V, Douoguih M, Hemingway-Foday J, Wesche D, Ryder RW *et al*: Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic *Plasmodium falciparum* infections in Kinshasa DRC. *Malar J* 2011, 10:49.
 28. Osarfo J, Tagbor H, Cairns M, Alifrangis M, Magnussen P: Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial. *Trop Med Int Health* 2017, 22(8):1043-1052.